Expert Opinion On Therapeutic Targets impact factor, indexing, ranking (2024)


expert

Aim and Scope

The Expert Opinion On Therapeutic Targets is a research journal that publishes research related to Biochemistry, Genetics and Molecular Biology; Pharmacology, Toxicology and Pharmaceutics. This journal is published by the Taylor and Francis Ltd.. The ISSN of this journal is 14728222, 17447631. Based on the Scopus data, the SCImago Journal Rank (SJR) of expert opinion on therapeutic targets is 1.581.

Also, please check the following important details about expert opinion on therapeutic targets: Publisher, ISSN, Ranking, Indexing, Impact Factor (if applicable), Publication fee (APC), Review Time, and Acceptance Rate.

According to Clarivate's JCR, journals indexed in SCIE/SSCI have an impact factor.

Expert Opinion On Therapeutic Targets Ranking

Impact Factor: 4.6
5-Year JIF: 6.3
SJR (SCImago Journal Rank): 1.581
Quartile: Q1

The latest Impact Factor list (JCR) is released in June 2024.

The Impact Factor of Expert Opinion On Therapeutic Targets is 4.6.

The impact factor (IF) is a measure of the frequency with which the average article in a journal has been cited in a particular year. It is used to measure the importance or rank of a journal by calculating the times its articles are cited.

The impact factor was devised by Eugene Garfield, the founder of the Institute for Scientific Information (ISI) in Philadelphia. Impact factors began to be calculated yearly starting from 1975 for journals listed in the Journal Citation Reports (JCR). ISI was acquired by Thomson Scientific & Healthcare in 1992, and became known as Thomson ISI. In 2018, Thomson-Reuters spun off and sold ISI to Onex Corporation and Baring Private Equity Asia. They founded a new corporation, Clarivate, which is now the publisher of the JCR.


Important Metrics

Journal Title: Expert Opinion on Therapeutic Targets
Publisher: Taylor and Francis Ltd.
ISSN: 14728222, 17447631
Type: journal
Journal Scope: Biochemistry, Genetics and Molecular Biology; Pharmacology, Toxicology and Pharmaceutics
Country: United Kingdom
H-Index: 101
SJR: 1.581
Quartile: Clinical Biochemistry (Q1); Drug Discovery (Q1); Molecular Medicine (Q1); Pharmacology (Q1)

Indexing

The expert opinion on therapeutic targets is indexed in:

An indexed journal means that the journal has gone through and passed a review process of certain requirements done by a journal indexer.

The Web of Science Core Collection includes the Science Citation Index Expanded (SCIE), Social Sciences Citation Index (SSCI), Arts & Humanities Citation Index (AHCI), and Emerging Sources Citation Index (ESCI).


Expert Opinion On Therapeutic Targets Impact Factor 2024

The latest impact factor of expert opinion on therapeutic targets is 4.6 which is recently updated in June, 2024.

The impact factor (IF) is a measure of the frequency with which the average article in a journal has been cited in a particular year. It is used to measure the importance or rank of a journal by calculating the times it's articles are cited.

Note: Every year, The Clarivate releases the Journal Citation Report (JCR). The JCR provides information about academic journals including impact factor. The latest JCR was released in June, 2023. The JCR 2024 will be released in the June 2024.


Quartile

The latest Quartile of expert opinion on therapeutic targets is Q1.

Each subject category of journals is divided into four quartiles: Q1, Q2, Q3, Q4. Q1 is occupied by the top 25% of journals in the list; Q2 is occupied by journals in the 25 to 50% group; Q3 is occupied by journals in the 50 to 75% group and Q4 is occupied by journals in the 75 to 100% group.


Journal Publication Time

The publication time may vary depending on factors such as the complexity of the research and the current workload of the editorial team. Journals typically request reviewers to submit their reviews within 3-4 weeks. However, some journals lack mechanisms to enforce this deadline, making it difficult to predict the duration of the peer review process.

The review time also depends upon the quality of the research paper.



Call for Papers

Visit to the official website of the journal/ conference to check the details about call for papers.

How to publish in Expert Opinion On Therapeutic Targets?

If your research is related to Biochemistry, Genetics and Molecular Biology; Pharmacology, Toxicology and Pharmaceutics, then visit the official website of expert opinion on therapeutic targets and send your manuscript.

Tips for publishing in Expert Opinion On Therapeutic Targets:

Acceptance Rate

Acceptance rate is the ratio of the number of articles submitted to the number of articles published. Researchers can check the acceptance rate on the journal website. Alternatively, they can contact the editor of the journal.

Final Summary

  • The impact factor of expert opinion on therapeutic targets is 4.6.
  • The expert opinion on therapeutic targets is a reputed research journal.
  • It is published by Taylor and Francis Ltd..
  • The journal is indexed in UGC CARE, Scopus, SCIE, PubMed.
  • The (SJR) SCImago Journal Rank is 1.581.

Sources: expert opinion on therapeutic targets







SIMILIAR JOURNALS


CHEMICO-BIOLOGICAL INTERACTIONS

ISSN: 0009-2797
Publisher: ELSEVIER IRELAND LTD

EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY

ISSN: 1742-5255
Publisher: TAYLOR & FRANCIS LTD

DNA AND CELL BIOLOGY

ISSN: 1044-5498
Publisher: MARY ANN LIEBERT, INC

JOURNAL OF MOLECULAR EVOLUTION

ISSN: 0022-2844
Publisher: SPRINGER

MOLECULAR BIOLOGY AND EVOLUTION

ISSN: 0737-4038
Publisher: OXFORD UNIV PRESS

MOLECULAR PHYLOGENETICS AND EVOLUTION

ISSN: 1055-7903
Publisher: ACADEMIC PRESS INC ELSEVIER SCIENCE

ONCOGENE

ISSN: 0950-9232
Publisher: SPRINGERNATURE

MOLECULAR REPRODUCTION AND DEVELOPMENT

ISSN: 1040-452X
Publisher: WILEY

COMPARATIVE BIOCHEMISTRY AND PHYSIOLOGY C-TOXICOLOGY & PHARMACOLOGY

ISSN: 1532-0456
Publisher: ELSEVIER SCIENCE INC

ENVIRONMENTAL POLLUTANTS AND BIOAVAILABILITY

ISSN: 2639-5932
Publisher: TAYLOR & FRANCIS LTD

TOP RESEARCH JOURNALS

Credit and Source: Scopus, Clarivate, UGC CARE.